Oregon Public Employees Retirement Fund Has $5.80 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Oregon Public Employees Retirement Fund grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 9,071 shares of the company’s stock after purchasing an additional 2,146 shares during the period. Oregon Public Employees Retirement Fund’s holdings in IDEXX Laboratories were worth $5,795,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of IDXX. STF Management LP boosted its stake in IDEXX Laboratories by 1.3% in the second quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after buying an additional 16 shares in the last quarter. Clearstead Trust LLC lifted its holdings in shares of IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after acquiring an additional 16 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after purchasing an additional 16 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in shares of IDEXX Laboratories by 3.3% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after purchasing an additional 17 shares during the last quarter. Finally, Stratos Wealth Partners LTD. increased its position in IDEXX Laboratories by 1.7% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after purchasing an additional 18 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 0.1%

Shares of IDXX opened at $713.35 on Friday. The company has a market capitalization of $56.96 billion, a PE ratio of 56.57, a PEG ratio of 3.81 and a beta of 1.67. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The stock’s 50-day moving average price is $706.93 and its two-hundred day moving average price is $643.84. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm posted $2.80 earnings per share. The business’s quarterly revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IDXX. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. UBS Group raised their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. JPMorgan Chase & Co. lifted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Morgan Stanley boosted their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.